Show simple item record

dc.contributor.authorTrabert, B
dc.contributor.authorPoole, EM
dc.contributor.authorWhite, E
dc.contributor.authorVisvanathan, K
dc.contributor.authorAdami, H-O
dc.contributor.authorAnderson, GL
dc.contributor.authorBrasky, TM
dc.contributor.authorBrinton, LA
dc.contributor.authorFortner, RT
dc.contributor.authorGaudet, M
dc.contributor.authorHartge, P
dc.contributor.authorHoffman-Bolton, J
dc.contributor.authorJones, M
dc.contributor.authorLacey, JV
dc.contributor.authorLarsson, SC
dc.contributor.authorMackenzie, GG
dc.contributor.authorSchouten, LJ
dc.contributor.authorSandler, DP
dc.contributor.authorO'Brien, K
dc.contributor.authorPatel, AV
dc.contributor.authorPeters, U
dc.contributor.authorPrizment, A
dc.contributor.authorRobien, K
dc.contributor.authorSetiawan, VW
dc.contributor.authorSwerdlow, A
dc.contributor.authorvan den Brandt, PA
dc.contributor.authorWeiderpass, E
dc.contributor.authorWilkens, LR
dc.contributor.authorWolk, A
dc.contributor.authorWentzensen, N
dc.contributor.authorTworoger, SS
dc.contributor.authorOvarian Cancer Cohort Consortium (OC3)
dc.date.accessioned2018-04-30T14:55:38Z
dc.date.issued2019-02
dc.identifier.citationJournal of the National Cancer Institute, 2019, 111 (2), pp. 137 - 145
dc.identifier.issn0027-8874
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1664
dc.identifier.eissn1460-2105
dc.identifier.doi10.1093/jnci/djy100
dc.description.abstractBACKGROUND:Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily and low-dose users. To prospectively investigate associations of analgesic use with ovarian cancer, we analyzed data from 13 studies in the Ovarian Cancer Cohort Consortium (OC3). METHODS:The current study included 758 829 women who at study enrollment self-reported analgesic use, among whom 3514 developed ovarian cancer. Using Cox regression, we assessed associations between frequent medication use and risk of ovarian cancer. Dose and duration were also evaluated. All statistical tests were two-sided. RESULTS:Women who used aspirin almost daily (≥6 days/wk) vs infrequent/nonuse experienced a 10% reduction in ovarian cancer risk (rate ratio [RR] = 0.90, 95% confidence interval [CI] = 0.82 to 1.00, P = .05). Frequent use (≥4 days/wk) of aspirin (RR = 0.95, 95% CI = 0.88 to 1.03), nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs; RR = 1.00, 95% CI = 0.90 to 1.11), or acetaminophen (RR = 1.05, 95% CI = 0.88 to 1.24) was not associated with risk. Daily acetaminophen use (RR = 1.28, 95% CI = 1.00 to 1.65, P = .05) was associated with elevated ovarian cancer risk. Risk estimates for frequent, long-term (10+ years) use of aspirin (RR = 1.15, 95% CI = 0.98 to 1.34) or nonaspirin NSAIDs (RR = 1.19, 95% CI = 0.84 to 1.68) were modestly elevated, although not statistically significantly so. CONCLUSIONS:This large, prospective analysis suggests that women who use aspirin daily have a slightly lower risk of developing ovarian cancer (∼10% lower than infrequent/nonuse)-similar to the risk reduction observed in case-control analyses. The observed potential elevated risks for 10+ years of frequent aspirin and NSAID use require further study but could be due to confounding by medical indications for use or variation in drug dosing.
dc.formatPrint
dc.format.extent137 - 145
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectOvarian Cancer Cohort Consortium (OC3)
dc.subjectHumans
dc.subjectOvarian Neoplasms
dc.subjectAspirin
dc.subjectAnalgesics
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectPrognosis
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subjectFollow-Up Studies
dc.subjectProspective Studies
dc.subjectMiddle Aged
dc.subjectUnited States
dc.subjectEurope
dc.subjectFemale
dc.titleAnalgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.
dc.typeJournal Article
dcterms.dateAccepted2018-04-30
rioxxterms.versionofrecord10.1093/jnci/djy100
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2019-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of the National Cancer Institute
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology
pubs.publication-statusPublished
pubs.volume111
pubs.embargo.termsNot known
icr.researchteamAetiological Epidemiologyen_US
dc.contributor.icrauthorSwerdlow, Anthonyen
dc.contributor.icrauthorJones, Michaelen


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record